Search

Your search keyword '"Velders, Gerjo A."' showing total 31 results
Start Over Author "Velders, Gerjo A."
31 results on '"Velders, Gerjo A."'

1. The effect of administering preprocedural VITamin K on the international normalized ratio in patients anticoagulated with ACEnocoumarol (VITKACE-study): a prospective cohort study

Author

Bijkerk, Stella, Lourens, Harm J., Mares, Wout G.N., van Kampen, Corine A., van der Veen, Maurits J., Adriaansen, Henk J., Ponfoort, Erik D., Festen, Barbara, Westendorp, G. Wouter, Rovers, Jörgen M.P., Groot, Gerie M.C., Bootsma, Hans-Peter R., Amelung, Linde M., Bins, Sander, Velders, Gerjo, and Bemelmans, Remy H.H.

Published
2024
Full Text
View/download PDF

2. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma

Author

van Bladel, Diede A. G., Stevens, Wendy B. C., Kroeze, Leonie I., de Groen, Ruben A. L., de Groot, Fleur A., van der Last-Kempkes, Jessica L. M., Berendsen, Madeleine R., Rijntjes, Jos, Luijks, Jeroen A. C. W., Bonzheim, Irina, van der Spek, Ellen, Plattel, Wouter J., Pruijt, Johannes F. M., de Jonge-Peeters, Susan D. P. W. M., Velders, Gerjo A., Lensen, Chantal, van Bladel, Esther R., Federmann, Birgit, Hoevenaars, Brigiet M., Pastorczak, Agata, van der Werff ten Bosch, Jutte, Vermaat, Joost S. P., Nooijen, Peet T. G. A., Hebeda, Konnie M., Fend, Falko, Diepstra, Arjan, van Krieken, J Han J. M., Groenen, Patricia J. T. A., van den Brand, Michiel, and Scheijen, Blanca

Published
2023
Full Text
View/download PDF

3. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., and Levin, Mark-David

Published
2023
Full Text
View/download PDF

4. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

Author

Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

5. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A, Mellink, Clemens, van der Kevie-Kersemaekers, Anne-Marie F, Evers, Ludo M, de Boer, Fransien, Koene, Harry R, Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A, van der Spek, Ellen, van der Straaten, Hanneke M, Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F M, Visser, Hein P J, Houtenbos, Ilse, Idink, Cecile A M, Issa, Djamila E, Dompeling, Ellen C, van Zaanen, Henk C T, Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W, Terpstra, Wim E, Tonino, Sanne H, Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark-David, and Kater, Arnon P

Published
2022
Full Text
View/download PDF

6. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, and Zweegman, Sonja

Published
2021
Full Text
View/download PDF

7. The effect of administering preprocedural VITamin K on the international normalized ratio in patients anticoagulated with ACEnocoumarol (VITKACE-study): a prospective cohort study

Author

Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Medisch Oncologische Disciplines, Bijkerk, Stella, Lourens, Harm J., Mares, Wout G.N., van Kampen, Corine A., van der Veen, Maurits J., Adriaansen, Henk J., Ponfoort, Erik D., Festen, Barbara, Westendorp, G. Wouter, Rovers, Jörgen M.P., Groot, Gerie M.C., Bootsma, Hans Peter R., Amelung, Linde M., Bins, Sander, Velders, Gerjo, Bemelmans, Remy H.H., Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Medisch Oncologische Disciplines, Bijkerk, Stella, Lourens, Harm J., Mares, Wout G.N., van Kampen, Corine A., van der Veen, Maurits J., Adriaansen, Henk J., Ponfoort, Erik D., Festen, Barbara, Westendorp, G. Wouter, Rovers, Jörgen M.P., Groot, Gerie M.C., Bootsma, Hans Peter R., Amelung, Linde M., Bins, Sander, Velders, Gerjo, and Bemelmans, Remy H.H.

Published
2024

8. Assessing frailty in myeloma:The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Author

Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark David, Regelink, Josien C., Timmers, Gert Jan, de Waal, Esther G.M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B.L., van Kampen, Roel J.W., Stege, Claudia A.M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W.C.J., Ypma, Paula F., Zweegman, Sonja, Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark David, Regelink, Josien C., Timmers, Gert Jan, de Waal, Esther G.M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B.L., van Kampen, Roel J.W., Stege, Claudia A.M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W.C.J., Ypma, Paula F., and Zweegman, Sonja

Published
2024

9. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Author

Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, de Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B. L., van Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W. C. J., Ypma, Paula F., and Zweegman, Sonja

Published
2024
Full Text
View/download PDF

10. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Author

de Weerdt, Iris, Hofland, Tom, de Boer, Renate, Dobber, Johan A., Dubois, Julie, van Nieuwenhuize, Denise, Mobasher, Mehrdad, de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Remmerswaal, Ester B.M., Bemelman, Frederike J., Niemann, Carsten U., Kersting, Sabina, Levin, Mark-David, Eldering, Eric, Tonino, Sanne H., and Kater, Arnon P.

Published
2019
Full Text
View/download PDF

11. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

van der Straten, Lina, primary, Stege, Claudia A. M., additional, Kersting, Sabina, additional, Nasserinejad, Kazem, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H. M., additional, van der Kevie-Kersemaekers, Anne-Marie F., additional, Evers, Ludo M., additional, de Boer, Fransien, additional, Koene, Harry R., additional, Schreurs, John, additional, van der Klift, Marjolein, additional, Velders, Gerjo A., additional, van der Spek, Ellen, additional, van der Straaten, Hanneke M., additional, Hoogendoorn, Mels, additional, van Gelder, Michel, additional, Posthuma, Eduardus F. M., additional, Visser, Hein P. J., additional, Houtenbos, Ilse, additional, Idink, Cecile A. M., additional, Issa, Djamila E., additional, Dompeling, Ellen C., additional, van Zaanen, Henk C. T., additional, Veelken, J. Hendrik, additional, Levenga, Henriette, additional, Tick, Lidwine W., additional, Terpstra, Wim E., additional, Tonino, Sanne H., additional, Westerweel, Peter E., additional, Langerak, Anton W., additional, Kater, Arnon P., additional, and Levin, Mark-David, additional

Published
2023
Full Text
View/download PDF

12. P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

Author

Groen, Kaz, primary, Stege, Claudia, additional, Nasserinejad, Kazem, additional, de Heer, Koen, additional, van Kampen, Roel J.W., additional, Leys, Rineke B.L., additional, Thielen, Noortje, additional, Westerman, Matthijs, additional, Wu, Ka-Lung, additional, Ludwig, Inge, additional, Issa, Djamila E., additional, Velders, Gerjo A., additional, Vekemans, Marie-Christiane, additional, van de Donk, Niels W.C.J., additional, Timmers, Gert-Jan, additional, de Boer, Fransien, additional, Tick, Lidwine W., additional, van der Spek, Ellen, additional, de Waal, Esther G.M., additional, Sohne, Maaike, additional, Sonneveld, Pieter, additional, Nijhof, Inger S., additional, Klein, Saskia K., additional, Levin, Mark-David, additional, Ypma, Paula F., additional, and Zweegman, Sonja, additional

Published
2023
Full Text
View/download PDF

13. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma:an open-label phase 2 trial

Author

Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie Christiane, Timmers, Gert Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark David, Ypma, Paula F., Zweegman, Sonja, Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie Christiane, Timmers, Gert Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark David, Ypma, Paula F., and Zweegman, Sonja

Abstract

Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. Methods:In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297.Findings: Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Interpretation: Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate-fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate-fi

Published
2023

15. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe):primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Author

Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, Kater, Arnon P., Kersting, Sabina, Dubois, Julie, Nasserinejad, Kazem, Dobber, Johan A., Mellink, Clemens, van der Kevie-Kersemaekers, Anne Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F.M., Visser, Hein P.J., Houtenbos, Ilse, Idink, Cecile A.M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C.T., Veelken, Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Boyer, Michelle, Mobasher, Mehrdad, Levin, Mark David, and Kater, Arnon P.

Abstract

Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status. Methods: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands. Eligible patients were aged 18 years or older with previously untreated chronic lymphocytic leukaemia, had an ECOG performance status of 0–2, and were unfit for fludarabine-based treatment. All patients received two debulking cycles of intravenous obinutuzumab (100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8, 15, and day 1 of cycle two), followed by fixed-duration venetoclax plus obinutuzumab for 12 cycles (six cycles of intravenous obinutuzumab 1000 mg on day 1 and 12 during 28-day cycles of oral venetoclax, starting with a 5-week ramp-up and then 400 mg once daily until completion of cycle 12). Patients were then randomly assigned (1:1) by minimal residual disease status in peripheral blood, to receive either 12 cycles of venetoclax consolidation irrespective of minimal residual disease or venetoclax consolidation only if minimal residual disease was detected at randomisation. The primary endpoint was undetectable minimal residual disease in bone marrow and no progressive disease 3 months after end of consolidation treatment (or corresponding timepoint) by intention-to-treat. Safety was assessed in all patients who received at least one dose of any study drug. This is the primary endpoint analysis of this trial, which is ongoing and is registered with EudraCT (2015-004985-27). Findings: Between Oct 28, 2016, and May 31, 2018, 70 patients were enrolled

Published
2022

17. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Author

Groen, Kaz, primary, Stege, Claudia A.M., additional, Nasserinejad, Kazem, additional, de Heer, Koen, additional, Van Kampen, Roel J.W., additional, Leijs, Maria B.L., additional, Thielen, Noortje, additional, Westerman, Matthijs, additional, Wu, Ka Lung, additional, Ludwig, Inge, additional, Issa, Djamila, additional, Velders, Gerjo A., additional, Vekemans, Marie-Christiane, additional, van de Donk, Niels W.C.J., additional, Timmers, Gert-Jan, additional, Sonneveld, Pieter, additional, Seefat, Maarten R., additional, Croon-de Boer, Fransien, additional, Tick, Lidwine W., additional, van der Spek, Ellen, additional, De Waal, Esther G.M., additional, Sohne, Maaike, additional, Ypma, Paula F, additional, Nijhof, Inger S., additional, Klein, Saskia K., additional, Levin, Mark-David, additional, and Zweegman, Sonja, additional

Published
2021
Full Text
View/download PDF

18. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, Zweegman, Sonja, Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, and Zweegman, Sonja

Published
2021

19. P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

Author

Groen, Kaz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark-David, Regelink, Josien, Timmers, Gert-Jan, de Waal, Esther, Westerman, Matthijs, Velders, Gerjo, de Heer, Koen, Leys, Rineke, van Kampen, Roel, Stege, Claudia, Seefat, Maarten, Nijhof, Inger, van der Spek, Ellen, Klein, Saskia, van de Donk, Niels, Ypma, Paula, and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

24. Polycytemie bij een patiënte met een uterusmyoom

Author

De Boer, Jolien P., Velders, Gerjo, Aliredjo, Riena, Scheenjes, Eduard, and Flinsenberg, Thijs W.H.

Subjects
Medicine(all), hemic and lymphatic diseases
Abstract

Myomatous erythrocytosis syndrome (MES) is characterised by a combination of polycythaemia, uterus myomatosus and the normalisation of erythrocyte count after hysterectomy. Case description A 58yearold postmenopausal woman was referred to the gynaecologist with symptoms of vaginal blood loss, increased abdominal circumference and pollakiuria. Physical examination indicated her uterus was enlarged to the size of a 24week gestation. Endometrial malignancy was excluded and ultrasound showed a myoma. In consultation with the patient a hysterectomy was planned. Preoperative blood tests showed increased haemoglobin levels (14.2 mmol/l). No indications of polycythaemia vera or secondary polycythaemia were found after which the diagnosis of MES was made. Haemoglobin levels normalised after hysterectomy without any further intervention. Conclusion MES is common, although relatively unknown. Its pathophysiology is most likely based on ectopic production of erythropoietin by leiomyoma tissue. The combination of polycythaemia and uterus myomatosus should alert clinicians to this syndrome, especially as polycythaemia normalises after hysterectomy.

Published
2017

25. First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Author

de Weerdt, Iris, primary, Hofland, Tom, additional, Dobber, Johan, additional, Dubois, Julie, additional, Eldering, Eric, additional, Mobasher, Mehrdad, additional, Croon-de Boer, Fransien, additional, Hoogendoorn, Mels, additional, Velders, Gerjo A., additional, van der Klift, Marjolein, additional, Levin, Mark-David, additional, Kersting, Sabina, additional, Tonino, Sanne, additional, and Kater, Arnon P., additional

Published
2018
Full Text
View/download PDF

26. Polycytemie bij een patiënte met een uterusmyoom

Author

Unit Opleiding Aios, De Boer, Jolien P., Velders, Gerjo, Aliredjo, Riena, Scheenjes, Eduard, Flinsenberg, Thijs W.H., Unit Opleiding Aios, De Boer, Jolien P., Velders, Gerjo, Aliredjo, Riena, Scheenjes, Eduard, and Flinsenberg, Thijs W.H.

Published
2017

27. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

Author

Abouyahya, Imane, primary, Alhan, Canan, additional, Westers, Theresia M., additional, te Boekhorst, Peter A., additional, Kappers-Klunne, Mies C., additional, Coenen, Jules L., additional, Heyning, Fenna H., additional, Huls, Gerwin A., additional, de Wolf, Joost T., additional, Imholz, Alex L., additional, Koene, Harry R., additional, Veth, Gerda, additional, de Kruijf, Evert-Jan F. M., additional, Muus, Petra, additional, Planken, Erwin V., additional, Segeren, Christine M., additional, Vasmel, Wies L., additional, van der Velden, Ankie M., additional, Velders, Gerjo A., additional, Koedam, Jan, additional, Ossenkoppele, Gert J., additional, and van de Loosdrecht, Arjan A., additional

Published
2012
Full Text
View/download PDF

29. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.

Author

Abouyahya, Imane, Alhan, Canan, Westers, Theresia M., te Boekhorst, Peter A., Kappers-Klunne, Mies C., Coenen, Jules L., Heyning, Fenna H., Huls, Gerwin A., de Wolf, Joost T., Imholz, Alex L., Koene, Harry R., Veth, Gerda, de Kruijf, Evert-Jan F. M., Muus, Petra, Planken, Erwin V., Segeren, Christine M., Vasmel, Wies L., van der Velden, Ankie M., Velders, Gerjo A., and Koedam, Jan

Subjects
MYELODYSPLASTIC syndromes treatment, CHROMOSOMES, NEUTROPHILS, PLATELET count
Abstract

The article discusses research which investigated the effectiveness of lenalidomide in treating patients with myelodysplastic syndromes (MDS) associated with partial chromosome 5 deletion. Topics explored include the classification of MDS according to the World Health Organization (WHO), the patients' response to treatment in terms of absolute neutrophil count and platelet count, and the clinical characteristics of patients involved in the study.

Published
2013
Full Text
View/download PDF

30. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Author

Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, and Koene HR

Subjects
Adolescent, Adult, Aged, Drug Administration Schedule, Drug Dosage Calculations, Female, Humans, Male, Middle Aged, Purpura, Thrombocytopenic, Idiopathic immunology, Purpura, Thrombocytopenic, Idiopathic mortality, Purpura, Thrombocytopenic, Idiopathic pathology, Recurrence, Rituximab, Survival Analysis, Treatment Outcome, Antibodies, Monoclonal, Murine-Derived therapeutic use, Immunologic Factors therapeutic use, Purpura, Thrombocytopenic, Idiopathic drug therapy
Published
2015
Full Text
View/download PDF

31. Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.

Author

de Kruijf EJ, Hagoort H, Velders GA, Fibbe WE, and van Pel M

Subjects
Animals, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cells drug effects, Hematopoietic Stem Cells physiology, Membrane Proteins administration & dosage, Mice, Mice, Inbred Strains, Time Factors, Hematopoietic Stem Cell Mobilization methods, Membrane Proteins pharmacology
Abstract

Background: Flt3-ligand is a cytokine that induces relatively slow mobilization of hematopoietic cells in animals and humans in vivo. This provides a time-frame to study hematopoietic stem and progenitor cell migration kinetics in detail., Design and Methods: Mice were injected with Flt3-ligand (10 microg/day, intraperitoneally) for 3, 5, 7 and 10 days. Mobilization of hematopoietic stem and progenitor cells was studied using colony-forming-unit granulocyte/monocyte and cobblestone-area-forming-cell assays. The radioprotective capacity of mobilized peripheral blood mononuclear cells was studied by transplantation of 1.5 x 10(6) Flt3-ligand-mobilized peripheral blood mononuclear cells into lethally irradiated (9.5 Gy) recipients., Results: Hematopoietic progenitor cell mobilization was detected from day 3 onwards and prolonged administration of Flt3-ligand produced a steady increase in mobilized progenitor cells. Compared to Flt3-ligand administration for 5 days, the administration of Flt3-ligand for 10 days led to a 5.5-fold increase in cobblestone-area-forming cells at week 4 and a 5.0-fold increase at week 5. Furthermore, transplantation of peripheral blood mononuclear cells mobilized by 5 days of Flt3-ligand administration did not radioprotect lethally irradiated recipients, whereas peripheral blood mononuclear cells mobilized by 10 days of Flt3-Ligand administration did provide 100% radioprotection of the recipients with significant multilineage donor chimerism. Compared to the administration of Flt3-ligand or interleukin-8 alone, co-administration of interleukin-8 and Flt3-ligand led to synergistic enhancement of hematopoietic stem and progenitor cell mobilization on days 3 and 5., Conclusions: These results indicate that hematopoietic stem and progenitor cells show different mobilization kinetics in response to Flt3-ligand, resulting in preferential mobilization of hematopoietic progenitor cells at day 5, followed by hematopoietic stem cell mobilization at day 10.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results